The risk of cardio-cerebral vascular events in type 2 diabetes patients with the usage of saxagliptin
碩士 === 高雄醫學大學 === 藥學系碩士在職專班 === 104 === Background: Saxagliptin is an oral hypoglycemic agent that can control blood sugar by inhibiting the metabolism of incretin. Several research studies recently showed that saxagliptin may increase the risk of cardiovascular events recetently. The aims of our st...
Main Authors: | ZI-Chen Wang, 王子誠 |
---|---|
Other Authors: | Pao-Chu Wu |
Format: | Others |
Language: | zh-TW |
Published: |
2016
|
Online Access: | http://ndltd.ncl.edu.tw/handle/40391727183387177674 |
Similar Items
-
Saxagliptin for type 2 diabetes
by: Antonio R Chacra, et al.
Published: (2010-09-01) -
Saxagliptin for type 2 diabetes
by: Chacra
Published: (2010-09-01) -
Sitagliptin versus saxagliptin in decompensated type 2 diabetes mellitus patients
by: Antonio Asti, et al.
Published: (2016-03-01) -
Profile of saxagliptin in the treatment of type 2 diabetes: focus on Japanese patients
by: Konya H, et al.
Published: (2014-07-01) -
Economic evaluation of type 2 diabetes treatment with saxagliptin in Colombia
by: Jorge F. Elgart, et al.
Published: (2012-02-01)